PDGFRB is an inclusion criterion in 2 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

Imatinib has evidence of efficacy in patients with PDGFRB mutation in myelodysplastic/myeloproliferative neoplasm [4].

PDGFRB is an inclusion criterion in 10 clinical trials for acute lymphoblastic leukemia, of which 9 are open and 1 is closed. Of the trials that contain PDGFRB status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].

PDGFRB is an inclusion criterion in 6 clinical trials for acute myeloid leukemia, of which 6 are open and 0 are closed. Of the trials that contain PDGFRB status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 5 are phase 2 (5 open) [4].

PDGFRB is an inclusion criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain PDGFRB status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [4].

PDGFRB is an inclusion criterion in 5 clinical trials for non-small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PDGFRB status and non-small cell lung carcinoma as inclusion criteria, 5 are phase 2 (3 open) [4].

PDGFRB is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain PDGFRB status and malignant solid tumor as inclusion criteria, 4 are phase 2 (3 open) [4].

PDGFRB is an inclusion criterion in 4 clinical trials for secondary acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain PDGFRB status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [4].

PDGFRB is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain PDGFRB status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [4].

PDGFRB is an inclusion criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain PDGFRB status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

PDGFRB is an inclusion criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain PDGFRB status and therapy-related acute myeloid leukemia as inclusion criteria, 3 are phase 2 (3 open) [4].

PDGFRB is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [4].

PDGFRB is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB status and breast carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

PDGFRB is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain PDGFRB status and cancer as inclusion criteria, 2 are phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB status and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 2 (2 open) [4].

PDGFRB is an inclusion criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [4].

PDGFRB is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB status and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and malignant glioma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PDGFRB status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for WHO grade II glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and WHO grade II glioma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRB is an inclusion criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [4].